You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)精神分裂症新药「瑞欣妥」开出首张处方
阿思达克 03-02 10:35
绿叶制药(02186.HK)表示,自主研发的注射用利培酮微球「瑞欣妥」於3月1日在山东开出首张处方,正式面向全国多个省市的医院和药房供药。

瑞欣妥用於治疗急性和慢性精神分裂症以及其他各种精神病性状态的明显的阳性症状和明显的阴性症状,可减轻与精神分裂症有关的情感症状。

集团表示,瑞欣妥从获得国家药品监督管理局的上市批准到首位患者的供应用药,仅用40多天,目前全球注册申报工作在同步开展,产品已在美国进入新药上市申请阶段,并在欧洲开展关键临床研究,其专利在中国、美国、欧洲、日本、韩国、俄罗斯、加拿大、澳大利亚均获得授权,专利期至2032年。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account